Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) Interest Coverage Ratio (2016 - 2025)

Protalix BioTherapeutics has reported Interest Coverage Ratio over the past 13 years, most recently at 690.83 for Q1 2025.

  • Quarterly results put Interest Coverage Ratio at 690.83 for Q1 2025, down 5448.29% from a year ago — trailing twelve months through Dec 2025 was 196.33 (down 24191.36% YoY), and the annual figure for FY2024 was 0.82, up 45.14%.
  • Interest Coverage Ratio for Q1 2025 was 690.83 at Protalix BioTherapeutics, down from 101.56 in the prior quarter.
  • Over the last five years, Interest Coverage Ratio for PLX hit a ceiling of 101.56 in Q4 2024 and a floor of 690.83 in Q1 2025.
  • Median Interest Coverage Ratio over the past 5 years was 4.1 (2023), compared with a mean of 37.47.
  • Biggest five-year swings in Interest Coverage Ratio: skyrocketed 650.63% in 2024 and later tumbled 5448.29% in 2025.
  • Protalix BioTherapeutics' Interest Coverage Ratio stood at 6.28 in 2021, then soared by 38.92% to 3.84 in 2022, then tumbled by 380.52% to 18.44 in 2023, then skyrocketed by 650.63% to 101.56 in 2024, then crashed by 780.22% to 690.83 in 2025.
  • The last three reported values for Interest Coverage Ratio were 690.83 (Q1 2025), 101.56 (Q4 2024), and 15.35 (Q3 2024) per Business Quant data.